OOIR: Observatory of International Research

Papers

(The median citation count of Presse Medicale is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Contents	94
Editorial board	68
Contents	57
Pancreatic islet organoids and organoids on-chip for type 1 diabetes	47
Immune checkpoint inhibitor-induced joint involvement	45
International variability in the diagnosis and management of disorders of consciousness	44
History of measles	39
Kidney disease in multiple myeloma	38
Evolving strategies in the management of transplant-eligible patients with newly diagnosed multiple myeloma	37
Towards etiological treatments in cardiomyopathies	34
Editorial board	34
Adverse effects of immune checkpoint inhibitors in the endocrine system	34
Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma	32
Pulmonary hypertension in sickle cell disease	27
Editorial board	26
Presentation of polymyalgia rheumatica and large joint polyarthritis in the spectrum of hyper-IgG4-related disease: A case report and literature review	25
The deep and the deeper: Spinal cord and deep brain stimulation for neuropathic pain	22
Cholera in Haiti	17
The current and future contribution of neuroimaging to the understanding of disorders of consciousness	17
Prognosis of consciousness disorders in the intensive care unit	16
Editorial board	15
Effects of thyroid disruption on neural cells stem fate in the mouse brain	15
Update on the pathogenetic hallmarks of chronic obstructive pulmonary disease	14
Heart failure with preserved ejection fraction: New challenges and new hopes	14
Gastrointestinal complications of immune checkpoint Inhibitor therapy	14

Editorial board	13
Cystic fibrosis	13
Renal hemodynamic changes in patients with type 2 diabetes and their clinical impact	13
Heart failure: A major public health problem	12
Contents	11
Contents	11
Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning	10
Risk stratification of acute pulmonary embolism	10
COVID-19 and kidney transplantation	10
The Spanish flu	10
A tribute to Guy Meyer	9
Neurological immune-related adverse events of immune-checkpoint inhibitors: an updated review	9
Imaging in multiple myeloma	8
Ethical, legal, and regulatory challenges in AI-based healthcare tools	8
Elderly patients with venous thromboembolism: Insights from the RIETE registry	8
Contents	8
Editorial board	8
Sickle cell disease and pregnancy	8
Contents	8
Contents	7
Decision-making for clinicians	7
Idiopathic pulmonary fibrosis	6
Vascular pathophysiology of sickle cell disease	6
Toxic and explosive risks in pharmacy: an underestimated reality	6
Contents	6
Bronchiectasis	5
Pre-COPD: Impact on prevention, detection, and treatment	5
Diagnostic management of acute pulmonary embolism	5
Preventative and curative treatment of venous thromboembolic disease in cancer patients	5
The liver in sickle cell disease	5
Health technology assessment in France	5
What's new in transplantation?	4
Primary ciliary dyskinesia	4
Lower-limb peripheral arterial disease and amputations in people with diabetes: Risk factors, prognostic value and management	4
Treatment of elderly and frail myeloma patients	4
HIV / AIDS as a model for emerging infectious disease: Origin, dating and circumstances of an emblematic epidemiological success	4
Life and death of smallpox	4
Vascular malformations	4
Capillary malformations updates on aetiopathogenesis, diagnosis, and management	4
Duration of anticoagulation of venous thromboembolism	4
Clinical pharmacology of antidiabetic drugs: What can be expected of their use?	3
Advancing the management of acute intermediate-high-risk pulmonary embolism: The enduring legacy of Professor Guy Meyer	3
Integrated care in COPD	3
The European reference network on rare lung diseases (ERN-LUNG) ambition to offer better lung health for all	3
The French way of HTA: Between scientific rigor, independence and transparency	3
Pulmonary toxicity of immune-checkpoint inhibitors	3
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today?	3
Electrical therapies in heart failure: Evolving technologies and indications	3
Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years	3
Adrenocortical organoids: A promising tool for modelling human physiology and translational research	3

Contents	2
Patient-reported outcome measures: A key to patient-tailored and outcome-driven care in pulmonary embolism survivors	2
Editorial	2
Update on dermatological toxicities of immune checkpoint inhibitors	2
Fecal microbiota transplantation: History, procedure and regulatory considerations	2
Chronic heart failure with reduced EF: A decade of major pharmacological innovations	2
Editorial	2
Contents	2
Sicca induced by immune checkpoint inhibitors	2
Yellow fever: A brief history of a tropical Virosis	2
Neuropathic pain: Evidence based recommendations	2
Editorial	2
Taking ethics into account: the HAS perspective	2